CCL2 and dementia: Regarding the controversies and the reasons for the differences among individual studies, we can add that, for example Mattsson et al. (2017) described increased levels of YKL-40 in the AD patients, when compared to controls and patients with stable MCI, but they did not find a statistically significant difference between groups (as mentioned above), while also different markers analyzed by this research group did not correlate with each other, except for YKL-40 versus CCL2 (chemokine C-C motif ligand 2) in patients with other dementias [25].